MGAT1 Activators
MGAT1 Activators represent a spectrum of chemical compounds that facilitate the enhancement of MGAT1's functional activity through various signaling pathways, primarily focusing on N-glycosylation processes. Forskolin and Rolipram, by raising cAMP levels and activating PKA, indirectly boost MGAT1's role in N-glycan branching, a critical component of protein folding and quality control. This enhancement is achieved through the modulation of enzymes and substrates involved in N-glycosylation pathways. Similarly, EGCG and LY294002 indirectly support MGAT1's functionality in glycosylation. EGCG, as a kinase inhibitor, and LY294002, as a PI3K inhibitor, affect the kinase-mediated signaling pathways, thereby influencing the N-glycosylation processes where MGAT1 is a key player. This is crucial for the proper folding and stability of glycoproteins.
Additionally, Ionomycin and PMA, through their effects on intracellular calcium levels and PKC activation respectively, contribute to enhancing MGAT1's role in N-glycosylation. These compounds affect calcium-dependent enzymes and PKC-mediated pathways, which are integral to the glycosylation process. U0126 and SB203580, targeting MEK1/2 and p38 MAPK pathways, further influence the glycosylation signaling. Their role in modulating these pathways indirectly enhances MGAT1's involvement in N-glycosylation, impacting protein folding and quality control. Furthermore, Trichostatin A, by altering gene expression patterns, and Sildenafil, through increasing cAMP/cGMP levels, support MGAT1's functional enhancement. TSA influences the expression of genes in glycosylation pathways, while Sildenafil enhances PKA and PKG activity, affecting pathways involved in N-glycosylation. Lastly, Resveratrol, acting through SIRT1, and BAY 11-7082, by inhibiting NF-κB activation, modify signaling dynamics. These actions potentially augment MGAT1's role in glycosylation processes, highlighting the intricate interplay of these activators in enhancing the functional activity of MGAT1 in N-glycosylation, a key process in protein folding and quality control.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. Elevated cAMP activates PKA, which can phosphorylate targets in glycosylation pathways. This may enhance MGAT1's function in N-glycan branching by modulating glycosylation processes, crucial for its role in protein folding and quality control. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram inhibits phosphodiesterase 4, leading to increased cAMP levels. Elevated cAMP can activate PKA, potentially enhancing MGAT1's activity in N-glycosylation by influencing enzymes and substrates involved in this pathway, crucial for proper protein glycosylation and function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits various protein kinases. By inhibiting kinases involved in glycosylation signaling pathways, EGCG could indirectly enhance MGAT1's role in N-glycosylation, which is essential for proper folding and stability of glycoproteins, thereby affecting protein quality control mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By modulating PI3K/AKT signaling, it may influence glycosylation pathways. This could indirectly enhance MGAT1's functionality in N-glycosylation, a process vital for the stability and function of many glycoproteins, by affecting the signaling networks regulating these pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin increases intracellular calcium levels, activating calcium-dependent signaling pathways. This can enhance MGAT1's role in N-glycosylation by modulating calcium-dependent enzymes and processes involved in glycosylation, thus affecting the protein folding and quality control in which MGAT1 plays a crucial role. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC). PKC activation can influence N-glycosylation pathways. This may enhance MGAT1's role in these processes by modulating enzymes and substrates involved in N-glycosylation, which is critical for the proper folding and function of glycoproteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK. By influencing glycosylation signaling pathways, it may enhance MGAT1's role in N-glycosylation, as MGAT1 is a mediator in protein glycosylation processes, particularly those involved in protein folding and quality control. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
TSA is a histone deacetylase inhibitor. By altering gene expression patterns, TSA can affect glycosylation pathways, potentially enhancing MGAT1's role in N-glycosylation, as it may influence the expression of genes involved in the glycosylation pathways where MGAT1 functions, impacting protein folding and quality control. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates SIRT1, a NAD+-dependent deacetylase. By modulating protein acetylation and gene expression, it can influence N-glycosylation pathways. This may enhance MGAT1's role in these processes, particularly in signaling networks where MGAT1 is involved in glycoprotein folding and quality control. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by blocking IκBα phosphorylation. This can shift cellular signaling dynamics, potentially enhancing MGAT1's role in N-glycosylation by influencing the signaling pathways where MGAT1 functions, particularly those involved in protein glycosylation and quality control. | ||||||